Bifogade filer
SynAct Pharma Q1 2025 Interim Report
Prenumeration
Du har en aktiv prenumeration.
Prenumerera på pressmeddelanden från SynAct Pharma via email.
Du prenumererar på följande språk.
Välj vilka språk du vill prenumerera på.
Modular Finance AB kommer att hantera vissa av dina personuppgifter om du väljer att prenumerera. Mer information om vår personuppgiftshantering finns här.
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
2025-05-27 07:30:00
SynAct Pharma AB (publ) (“SynAct”) today publishes the interim report for the first quarter 2025.
“SynAct Pharma has a remarkable drug candidate with resomelagon (AP1189). The data gained so far point to a significant change to how we help the body resolve excessive or chronic inflammation, situations when inflammation can overwhelm the immune system’s ability to counter the inflammation that can lead to suffering, tissue damage and loss of function.”
Jeppe Øvlesen, Chief Executive Officer and Board Member
First quarter 2025 (January – March)
- The Group’s net sales amounted to SEK 0 (0) thousand.
- Operating expenses amounted to SEK 28,098 (25,706) thousand, an increase of 9%.
- The Group’s loss after tax amounted to SEK 24,684 (24,906) thousand.
- The Group’s earnings per share before and after dilution amounted to -0.51 (-0.70) SEK.
- Cash flow from operating activities amounted to SEK -28,826 (-11,189) thousand.
- Cash flow from financing activities amounted to SEK 19,703 (-154) thousand.
- Cash flow for the period amounted to SEK -9,123 (-11,343) thousand.
- Cash and cash equivalents at the end of the period amounted to SEK 51,161 (51,553) thousand.
Significant events during the first quarter
- Jan 9 – SynAct Pharma AB announces outcome of the rights issue and resolves on a directed share issue to guarantors.
- Jan 31 – Change in number of shares and votes in SynAct Pharma AB.
- Feb 20 – SynAct’s Nomination Committee proposes Jeppe Ragnar Andersen to the Board.
- Mar 4 – Pivotal US Patent Protecting resomelagon (AP1189) Granted to SynAct Pharma.
- Mar 17 – The European Patent Office issues an Intention to Grant a European Patent Covering the Clinical Formulation of resomelagon (AP1189).
Significant events after the end of the period
- Apr 11 – SynAct Pharma Announces Initiation of Phase 2 Study with resomelagon (AP1189) for the Treatment of Patients with Dengue.
- Apr 23 – SynAct receives Notice of Allowance for grant of US Patent covering resomelagon (AP1189) combination therapy.
- May 12 – SynAct receives Issue Notification and Patent Term Adjustment for US patent covering resomelagon (AP1189) combination therapy.